Log In
Print this Print this

tofacitinib extended release (Xeljanz XR)

  Manage Alerts
Collapse Summary General Information
Company Pfizer Inc.
DescriptionOral extended-release pan-Janus kinase (JAK) inhibitor
Molecular Target Janus kinase-1 (JAK-1) ; Janus kinase-3 (JAK-3)
Mechanism of ActionJanus kinase-3 (JAK-3) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationRheumatoid arthritis (RA)
Indication DetailsTreat moderate to severe rheumatoid arthritis (RA) in patients who have had an inadequate response or intolerance to methotrexate
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today